OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case–control study in Paris, France
Ricardo Carbajal, Pierre‐Yves Boëlle, Aurélie Pham, et al.
The Lancet Child & Adolescent Health (2024) Vol. 8, Iss. 10, pp. 730-739
Closed Access | Times Cited: 7
Ricardo Carbajal, Pierre‐Yves Boëlle, Aurélie Pham, et al.
The Lancet Child & Adolescent Health (2024) Vol. 8, Iss. 10, pp. 730-739
Closed Access | Times Cited: 7
Showing 7 citing articles:
Nirsevimab decreased the subsequent risk of respiratory syncytial virus infection and wheezing in the 2023–2024 RSV season
Kevin Sheng-Kai, Serena Yun‐Chen Tsai, Chadi M. El Saleeby, et al.
Pediatric Research (2025)
Closed Access
Kevin Sheng-Kai, Serena Yun‐Chen Tsai, Chadi M. El Saleeby, et al.
Pediatric Research (2025)
Closed Access
Nirsevimab effectiveness on paediatric emergency visits for RSV bronchiolitis: a test-negative design study
Léa Lenglart, Yaël Levy, Romain Basmaci, et al.
European Journal of Pediatrics (2025) Vol. 184, Iss. 2
Closed Access
Léa Lenglart, Yaël Levy, Romain Basmaci, et al.
European Journal of Pediatrics (2025) Vol. 184, Iss. 2
Closed Access
Global Pediatric Pulmonology Alliance recommendations to protect all infants against respiratory syncytial virus with prophylactic monoclonal antibodies
Kunling Shen, Lance E. Rodewald, Yonghong Yang, et al.
Pediatric Investigation (2025)
Open Access
Kunling Shen, Lance E. Rodewald, Yonghong Yang, et al.
Pediatric Investigation (2025)
Open Access
Respiratory syncytial virus immunization with nirsevimab: Acceptance and satisfaction assessment in infants and risk groups in the region of Murcia (Spain)
Jaime Jesús Pérez Martín, María de la Cruz Gómez Moreno, Susana Sánchez Manresa, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Jaime Jesús Pérez Martín, María de la Cruz Gómez Moreno, Susana Sánchez Manresa, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Effectiveness of nirsevimab in reducing hospitalizations in emergency departments due to bronchiolitis among infants under 3 months: a retrospective study
Alexis Marouk, B. Verrat, Isabelle Pontais, et al.
European Journal of Pediatrics (2025) Vol. 184, Iss. 3
Closed Access
Alexis Marouk, B. Verrat, Isabelle Pontais, et al.
European Journal of Pediatrics (2025) Vol. 184, Iss. 3
Closed Access
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024
Ushma Wadia, Hannah C. Moore, Peter Richmond, et al.
Journal of Infection (2025), pp. 106466-106466
Open Access
Ushma Wadia, Hannah C. Moore, Peter Richmond, et al.
Journal of Infection (2025), pp. 106466-106466
Open Access
Nirsevimab: Daten der ersten RSV-Immunisierungskampagne in Frankreich
Pädiatrie up2date (2025) Vol. 20, Iss. 01, pp. 9-9
Closed Access
Pädiatrie up2date (2025) Vol. 20, Iss. 01, pp. 9-9
Closed Access
Nirsevimab—a breakthrough in respiratory syncytial virus bronchiolitis
Zein Assad, Jesse Papenburg, Naïm Ouldali
The Lancet Child & Adolescent Health (2024) Vol. 8, Iss. 10, pp. 708-709
Closed Access
Zein Assad, Jesse Papenburg, Naïm Ouldali
The Lancet Child & Adolescent Health (2024) Vol. 8, Iss. 10, pp. 708-709
Closed Access
